FDA Approves Oveporexton for Narcolepsy Type 1, First Drug to Treat Full Range of Symptoms

The FDA approved Oveporexton for the treatment of Narcolepsy Type 1 in August 2026, making it the first drug specifically designed to address the full range of NT1 symptoms.

Narcolepsy Type 1 is a chronic neurological disorder caused by the loss of hypocretin-producing neurons in the brain. Patients experience excessive daytime sleepiness, sudden muscle weakness triggered by emotion (cataplexy), sleep paralysis, and hallucinations at the onset of sleep.

Existing treatments address some symptoms but not all. Stimulants help with daytime sleepiness but do not treat cataplexy. Sodium oxybate addresses multiple symptoms but requires patients to wake up in the middle of the night to take a second dose.

Oveporexton works by activating hypocretin receptors in the brain, mimicking the function of the neurons that NT1 patients have lost. In clinical trials, the drug reduced cataplexy attacks and improved daytime alertness without the side effects associated with stimulants.

The FDA's approval covers adults with Narcolepsy Type 1. The agency reviewed data from two Phase 3 trials involving more than 600 patients.

Narcolepsy Type 1 affects an estimated 200,000 Americans. Many patients go undiagnosed for years because the condition is often mistaken for depression, laziness, or other sleep disorders.

Patient advocacy groups welcomed the approval. The Narcolepsy Network said the drug represents a meaningful advance for people who have struggled to find effective treatment.

The manufacturer has not yet announced a price for Oveporexton. Insurance coverage and patient access programs are expected to be announced in the coming weeks.